- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears Park’s MCAT system
Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.MCAT consists of
Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.
MCAT consists of macro-collimators that attach to standard detectors,creating a coded pattern that is detected by the camera's photomultipliertube array. Software decodes the pattern into a high-resolutionimage covering a wide range of energies. Park believes the techniqueis more versatile than coincidence-detection methods for oncologyimaging.
Park will show the MCAT module, as well as clinical images, atthe Society of Nuclear Medicine meeting in San Antonio, TX, inJune.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
